We also discuss the current preclinical status of pan- and isoform-selective histone deacetylase (HDAC) inhibitors, DNA methylation, and microRNA modulators and propose new research areas that may facilitate locus-specific epigenome editing as a novel therapeutic strategy for IPF and COPD. The gene discussed is HDAC9; the disease is idiopathic pulmonary fibrosis.